Pirmitegravir
Product Specifications
Product Name Alternative
STP0404
UNSPSC Description
Pirmitegravir is a potent and first-in-class inhibitor of allosteric integrase (ALLINI) that targets LEDGF/p75 binding site. Pirmitegravir displays picomolar IC50 in human PBMCs with a >24,000 therapeutic index against HIV-1. Pirmitegravir harbors outstanding anti-virus and safety properties[1].
Target Antigen
HIV; HIV Integrase
Type
Reference compound
Related Pathways
Anti-infection;Metabolic Enzyme/Protease
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/pirmitegravir.html
Purity
99.76
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C([C@H](C1=C(N=C(C2=C1C3=CC=C(C=C3)Cl)N(C(C)=C2C)CC4=CN(N=C4)C)C)OC(C)(C)C)O
Molecular Weight
495.01
References & Citations
[1]Maehigashi T, et al. A highly potent and safe pyrrolopyridine-based allosteric HIV-1 integrase inhibitor targeting host LEDGF/p75-integrase interaction site. PLoS Pathog. 2021;17(7):e1009671.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-130000/Pirmitegravir-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-130000/Pirmitegravir-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
2245231-10-9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
